Introducing Ciraplex® ULTRA Ultrasensitive Assays Combining the Power of Multiplexing with Ultrasensitivity
Ciraplex® ULTRA Ultrasensitive Assays with femtogram/ml (fg/ml) levels of detection address multiple biomarkers in a wide range of therapeutic areas. These kits offer enhanced sensitivity and an extended dynamic range providing quantification below standard detection limits. As well, intuitive Cira™ software streamlines the data management process providing exceptional data control.
The Cira™ immunoassay platform was specifically designed by a team of Aushon engineers and biologists to offer accurate multiplex biomarker analysis with simplicity and savings in mind. The Cira™ platform combines the accuracy and precision of ELISA, the sensitivity of chemiluminescence, and the throughput and affordability of multiplexing. The circular Ciraplex® format (patent-pending) offers enhanced accuracy and precision versus traditional protein array configurations. The Aushon menu features key biomarkers in a wide range of therapeutic areas being used to enhance knowledge and improve decision-making in translational medicine.
Cira Confidence: Ultrasensitivity Multiplexing Intuitive Simplicity Savings
Validation Report for
the Ciraplex® Human Cytokine 9-Plex Array:
IFNγ, IL-1α, IL-1β, IL-4, IL-6 IL-8, IL-10, IL-12p70,
TNFα (Active Trimer)
June 9, 2016 — Biocompare publishes article on multiplex immunoassay platforms, referencing the qualitative data and flexible customizations of Aushon's Ciraplex ULTRA assays and the fluidics associated with Aushon's circular format printing configuration. Read More
May 27, 2016 — Duke Medical Center's research on epithelial ovarian cancer using Aushon's Cira Technology presented at ASCO 2016.
May 19, 2016 — Genome Web Publishes Article on Aushon's move into the ultrasensitive immunoassay space through the development of a series of cytokine assays that can achieve sensitivity in the femtogram per ml range. Read More
May 17, 2016 — Dr. Maribeth Raines presents Comparison of Human
IL-6 Detection Across Multiple Immunoassay Platforms at the 2016 Biomarker World Congress. Read More